文献速递肾癌与肾肿瘤

转移性肾细胞癌一线至后续治疗中循环肿瘤DNA谱的演变

Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma.
PubMed 文献 · Eur Urol · 2017-04-14

该研究在220例转移性肾细胞癌患者中,采用73基因循环肿瘤DNA(ctDNA)平台检测基因组改变(GAs),并比较一线与后续治疗患者的ctDNA谱差异。78.6%的患者检出GAs,后续治疗者TP53、VHL、NF1、EGFR、PIK3CA改变频率更高,尤其在接受血管内皮生长因子抑制剂后。

要点

  • 78.6%的转移性肾细胞癌患者可检出ctDNA基因组改变。
  • 后续治疗者TP53(49% vs 24%)和NF1(20% vs 3%)改变频率高于一线治疗者。
  • 一线血管内皮生长因子抑制剂后TP53(64% vs 31%)和NF1(29% vs 4%)差异更明显。

核心结论

  • 在迄今最大规模的转移性肾细胞癌ctDNA基因组改变评估中,多数患者存在具有临床和生物学意义的基因组改变。
  • 一线血管内皮生长因子靶向治疗后,后续治疗患者中p53和雷帕霉素机制靶点通路(如NF1、PIK3CA)改变增加,可能构成耐药机制。
  • 在转移性肾细胞癌临床病程中常规进行ctDNA评估可能具有治疗意义。

研究设计与样本

  • 研究为在常规临床诊疗中于疾病进展时采用73基因临床实验室改进修正案认证的ctDNA平台进行ctDNA谱检测的转移性肾细胞癌患者队列。
  • 共纳入220例连续转移性肾细胞癌患者(145例男性,75例女性;中位年龄63岁,四分位距57-70岁)。
  • 基因组改变在全队列中汇总,并根据常规实践模式分组比较一线与一线后治疗(一线方案包括舒尼替尼、帕唑帕尼和贝伐珠单抗,一线后方案包括依维莫司、阿昔替尼、卡博替尼和纳武利尤单抗)。

主要发现

  • 78.6%的患者检出基因组改变。
  • 全队列中最常见的基因组改变为TP53(35%)、VHL(23%)、EGFR(17%)、NF1(16%)和ARID1A(12%)。
  • 分别有38例和64例患者被编码为接受一线和后续线治疗。
  • 一线后治疗与一线治疗相比,基因组改变频率差异最大者为TP53(49% vs 24%)、VHL(29% vs 18%)、NF1(20% vs 3%)、EGFR(15% vs 8%)和PIK3CA(17% vs 8%),而ARID1A相当(13% vs 11%)。
  • 将分析限制于后续线治疗与一线血管内皮生长因子抑制剂比较时,这些差异更为突出,尤其是TP53(64% vs 31%)和NF1(29% vs 4%)。

临床怎么用

  • 在转移性肾细胞癌临床病程中常规进行ctDNA评估可能具有治疗意义。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment of metastatic renal cell carcinoma (mRCC) typically entails mechanistically distinct agents across the first- and second-line setting. Activity of these agents may be predicated on selective pressure that modulates RCC biology. Circulating tumor DNA (ctDNA) is a platform to noninvasively ascertain temporal changes in genomic profile. OBJECTIVE: To assess the ctDNA profile in a large cohort of mRCC patients, and to assess changes across patients receiving first-line and later lines of therapy. DESIGN, SETTING, AND PARTICIPANTS: We obtained the ctDNA profile in mRCC patients who received ctDNA profiling as part of routine clinical care at progression using a 73-gene Clinical Laboratory Improvement Amendments-certified ctDNA platform. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Genomic alterations (GAs) were pooled for the entire cohort. A comparison of first- and postfirst-line was performed with grouping based on conventional practice patterns (first-line regimens included sunitinib, pazopanib, and bevacizumab, and postfirst-line regimens included everolimus, axitinib, cabozantinib, and nivolumab). RESULTS AND LIMITATIONS: ctDNA clinical results from a nationwide cohort of 220 consecutive patients with mRCC were assessed (145 men, 75 women; median age: 63 yr, interquartile range: 57-70). GAs were detected in 78.6% of patients. The most frequent GAs in the overall cohort included TP53 (35%), VHL (23%), EGFR (17%), NF1 (16%), and ARID1A (12%). Thirty-eight and 64 patients were coded as receiving first-line and later line agents, respectively. The highest disparity in GA frequencies in postfirst-line versus first-line were in TP53 (49% vs 24%), VHL (29% vs 18%), NF1 (20% vs 3%), EGFR (15% vs 8%), and PIK3CA (17% vs 8%) while ARID1A was equivalent (13% vs 11%). Restricting the analysis to later lines versus first-line vascular endothelial growth factor inhibitors, these differences were even more prominent, particularly for TP53 (64% vs 31%) and NF1 (29% vs 4%). CONCLUSIONS: In the largest assessment of ctDNA-detected GAs prevalence in mRCC to date, the majority of patients demonstrated clinically and biologically relevant GAs. Increasing p53 and mechanistic target of rapamycin pathway (eg, NF1, PIK3CA) alterations in postfirst-line patients with first-line vascular endothelial growth factor-directed therapy may underlie mechanisms of resistance. Routine ctDNA assessment during the clinical course of mRCC patients may have therapeutic implications. PATIENT SUMMARY: Collection of circulating tumor DNA is feasible in patients with metastatic renal cell carcinoma, and analysis of a large cohort demonstrates significant changes in circulating tumor DNA profile across patients' clinical course which may have therapeutic implications.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Pal SK, Sonpavde G, Agarwal N, et al. Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. Eur Urol. 2017. PMID: 28413127. doi:10.1016/j.eururo.2017.03.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。